UCB SA (OTCMKTS:UCBJF) Given Consensus Rating of “Buy” by Analysts

Shares of UCB SA (OTCMKTS:UCBJF) have been assigned a consensus rating of “Buy” from the six brokerages that are covering the company, Marketbeat reports. Six research analysts have rated the stock with a buy rating.

A number of research analysts have commented on the stock. Barclays reissued an “overweight” rating on shares of UCB in a research report on Tuesday, January 6th. Wolfe Research started coverage on shares of UCB in a research report on Monday, February 23rd. They issued an “outperform” rating for the company. The Goldman Sachs Group reiterated a “buy” rating on shares of UCB in a research note on Monday, February 16th. Finally, Stephens reissued an “overweight” rating on shares of UCB in a report on Thursday, January 15th.

UCB Price Performance

UCBJF stock opened at $325.56 on Tuesday. UCB has a 1-year low of $168.65 and a 1-year high of $345.39. The business has a 50-day moving average price of $310.66 and a 200 day moving average price of $295.30. The company has a debt-to-equity ratio of 0.33, a quick ratio of 0.78 and a current ratio of 1.19.

UCB Company Profile

UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.

Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.